联合治疗 UTHR 深 沪
交易中 03-25 11:44:56 美东时间
547.065
+15.245
+2.87%
华盛通- 最 高547.79
- 今 开536.94
- 成交量 12.27万股
- 最 低 536.92
- 昨 收 531.82
- 总市值 239.77亿
- 52周最高 548.12
- 市盈率 静 19.63
- 换手率 0.00%
- 52周最低 266.98
- 委 比 -92.86%
- 总股本 4382.77万
- 历史最高 548.12
- 量 比 0.72
- 振 幅 2.04%
- 历史最低 36.55
- 每 手 1
- 风险率 87.94%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 瑞穗上调MongoDB至"跑赢大市"，目标价从290美元升至325美元；麦格理下调小鹏评级至"中性" 目标价从24美元降至19美元
今日重点评级关注：HC Wainwright & Co.：维持Perspective Therapeutics"买入"评级，目标价从12美元升至13美元；Litchfield Hills：维持Star Equity Holdings"买入"评级，目标价从21美元升至28美元
03-24 10:07
Wells Fargo Maintains Equal-Weight on United Therapeutics, Raises Price Target to $486
Wells Fargo analyst Benjamin Burnett maintains United Therapeutics (NASDAQ:UTHR) with a Equal-Weight and raises the price target from $466 to $486.
03-23 21:22
United Therapeutics Chairperson and CEO Martine A. Rothblatt disposed of USD 3.92 million in common shares
United Therapeutics Chairperson and CEO Martine A. Rothblatt disposed of USD 3.92 million in common shares Martine Rothblatt, chairperson and CEO, reported disposing of common shares of United Therapeutics. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artifi
03-16 20:31
美股大行评级 | 潜在涨幅101%！甲骨文获花旗升目标价至320美元，维持"买入"评级
今日重点评级关注：Freedom Capital Markets：维持LifeMD"买入"评级，目标价从8美元升至10美元；Chardan Capital：维持Opus Genetics"买入"评级，目标价从9美元升至11美元
03-13 09:59
和黄医药达唯珂上市一年突发撤市 医保局同步移出商保创新药目录
①联合治疗组中观察到继发性血液系统恶性肿瘤相关不良事件，被认为属于上市后阶段可能出现的罕见严重风险； ②国家医保局火速宣布撤销达唯珂®在全国各省级医药采购平台的挂网资格，移出商保创新药目录； ③这一案例也可能对未来创新药医保体系准入机制产生一定影响。
03-09 22:04
United Therapeutics's board approves new $2B repurchase authorization; prices $1.5B ASR
United Therapeutics Corporation (UTHR) announced a stock repurchase program authorized by its board of directors, allowing for up to $2 billion in buybacks over the next year. The company has also sig...
03-09 19:37
BRIEF-United Therapeutics Unveils $2 Bln Buyback Plan, Launches $1.5 Bln Accelerated Repurchase
BRIEF-United Therapeutics Unveils $2 Bln Buyback Plan, Launches $1.5 Bln Accelerated Repurchase March 9 (Reuters) - United Therapeutics Corp UTHR.O : UNITED THERAPEUTICS CORPORATION ANNOUNCES $2 BILLION STOCK REPURCHASE AUTHORIZATION AND ENTERS INTO $1.5 BILLION ACCELERATED SHARE REPURCHASE PROGRAM
03-09 19:16
United Therapeutics Authorized New Stock Repurchase Program Of Up To $2B
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company's Board of Directors has authorized a new stock repurchase program of up to $2 billion over the next year. In
03-09 19:03
美股大行评级 | 最高582美元！博通获多家机构上调目标价；GENI、Okta、Rigetti Computing、Veeva Systems、Wix.com遭多家机构下调目标价
今日重点评级关注：韦德布什：维持TScan Therapeutics"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持莱斯康制药"买入"评级，目标价从4美元升至6美元
03-06 11:58
UBS Maintains Buy on United Therapeutics, Raises Price Target to $705
UBS analyst Ashwani Verma maintains United Therapeutics (NASDAQ:UTHR) with a Buy and raises the price target from $655 to $705.
03-05 23:24
